Inventor · disambiguated record
Shawn Lawrence
Also filed as: LAWRENCE SHAWN · LAWRENCE SHAWN M
26 granted patents·24 pending applications·161 citations·filing 2001–2025
96Inventor score
Files withREGENERON PHARMA44BETENBAUGH MICHAEL J1HUMAN GENOME SCIENCES INC1JARVIS DONALD1REGENERAN PHARMACEUTICALS INC1
Top patents by PatentIndex Score
50 records- 0198US12012445B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·4 cites·30 claims
- 0298US11958894B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0398US11732025B2Anti-VEGF protein compositions and methods for producing the sameREGENERAN PHARMACEUTICALS INC·Filed 2022·Granted Aug 22, 2023·11 cites·30 claims
- 0498US11548932B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Jan 10, 2023·8 cites·30 claims
- 0597US12012444B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·2 cites·19 claims
- 0697US11753459B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·5 cites·30 claims
- 0797US11535663B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Dec 27, 2022·6 cites·10 claims
- 0897US11472861B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Oct 18, 2022·5 cites·26 claims
- 0997US11104715B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2020·Granted Aug 31, 2021·5 cites·16 claims
- 1096US10927342B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2020·Granted Feb 23, 2021·23 cites·28 claims
- 1196US6949372B2Engineering intracellular sialylation pathwaysHUMAN GENOME SCIENCES INC·Filed 2001·Granted Sep 27, 2005·76 cites·98 claims
- 1295US12331341B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2022·Granted Jun 17, 2025·2 cites·14 claims
- 1394US12338274B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 24, 2025·0 cites·30 claims
- 1494US12319728B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 3, 2025·0 cites·30 claims
- 1594US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 1694US11332771B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2020·Granted May 17, 2022·3 cites·29 claims
- 1793US2024294606A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1890US12359166B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·29 claims
- 1990US12359165B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·30 claims
- 2088US12221619B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2023·Granted Feb 11, 2025·0 cites·30 claims
- 2188US2025340832A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2286US2025289868A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2385US2025327023A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2484US12163122B2Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variantsREGENERON PHARMA·Filed 2021·Granted Dec 10, 2024·1 cites·12 claims
- 2582US2023348532A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2682US2023331776A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2782US2023332084A1Bioreactor for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2882US2023287043A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2982US2023332201A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3082US2024010737A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3180US11312936B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2016·Granted Apr 26, 2022·1 cites·29 claims
- 3279US2022372436A1Serum-free cell culture mediumREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3378US7776565B2Engineering intracellular sialylation pathwaysUNIV JOHNS HOPKINS·Filed 2009·Granted Aug 17, 2010·2 cites·13 claims
- 3477US11970724B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2021·Granted Apr 30, 2024·0 cites·6 claims
- 3574US2025066718A1Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variantsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3672US2021388408A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3772US2021388407A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3871US12291563B2Metabolically optimized cell cultureREGENERON PHARMA·Filed 2022·Granted May 6, 2025·0 cites·15 claims
- 3968US11390663B2Metabolically optimized cell cultureREGENERON PHARMA·Filed 2016·Granted Jul 19, 2022·1 cites·15 claims
- 4067US2020255880A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4166US2020131554A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4266US2014273095A1Serum-Free Cell Culture MediumREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4365US2014024812A1Engineered intracellular sialylation pathwaysUNIV WYOMING·Filed 2013·Application pending·0 cites
- 4463US2019010531A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 4558US2005287637A1Engineering intracellular sialylation pathwaysBETENBAUGH MICHAEL J·Filed 2005·Application pending·0 cites
- 4657US2021087535A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4756US2016244725A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4854US2023063116A1Vegf mini-traps and method of use thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4952US8546105B2Engineering intracellular sialylation pathwaysJARVIS DONALD·Filed 2010·Granted Oct 1, 2013·0 cites·60 claims
- 5032US2016244726A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Shawn Lawrence files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →